Push launch MHRA approves GLP –one receptor agonist semaglutide to cut back risk of great heart complications in obese or overweight Older people Semaglutide is the main fat loss drug accredited in the UK as being a preventative treatment method for anyone with established heart problemsThere are also some uncomfortable side effects linked to it